A multicenter, uncontrolled clinical investigation of the contraceptive efficacy, cycle control and safety of a new low dose oral contraceptive containing 20 μg ethinyl estradiol and 100 μg levonorgestrel over six treatment cycles

Contraception

Volumn 56, Issue 5, 1997, Pages 285-290

  Bannemerschult, R ^a   Hanker, J P ^b   Wunsch C ^a   Fox, P ^a   Albring, M ^a   Brill, K ^a  

^a BAYER PHARMA AG   (Germany)

^b Krankenanstalten Mutter B ^*  (Germany)

Author keywords

Cycle control; Efficacy; Low dose oral contraceptive; Side effects

Indexed keywords

ETHINYLESTRADIOL PLUS LEVONORGESTREL; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTRACEPTION; DRUG EFFICACY; FEMALE; HORMONAL CONTRACEPTION; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENSTRUATION DISORDER; MULTICENTER STUDY; NAUSEA; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; TREATMENT OUTCOME; WEIGHT GAIN;

CLINICAL RESEARCH; CONTRACEPTION; CONTRACEPTIVE AGENTS, ESTROGEN--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS, FEMALE--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS, PROGESTIN--PHARMACODYNAMICS; CONTRACEPTIVE AGENTS--PHARMACODYNAMICS; CONTRACEPTIVE EFFECTIVENESS; CONTRACEPTIVE METHODS--SIDE EFFECTS; DEVELOPED COUNTRIES; DISEASES; ETHINYL ESTRADIOL--PHARMACODYNAMICS; EUROPE; FAMILY PLANNING; GERMANY; LEVONORGESTREL--PHARMACODYNAMICS; MENSTRUAL CYCLE; MENSTRUATION; MENSTRUATION DISORDERS; ORAL CONTRACEPTIVES, LOW-DOSE--SIDE EFFECTS; ORAL CONTRACEPTIVES--SIDE EFFECTS; REPRODUCTION; RESEARCH METHODOLOGY; RESEARCH REPORT; WESTERN EUROPE;

ADOLESCENT; ADULT; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FEMALE; HUMANS; LEVONORGESTREL; MENSTRUAL CYCLE; PATIENT COMPLIANCE; PREGNANCY; UTERINE HEMORRHAGE;

EID: 0031467272     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(97)00157-1     Document Type: Article

References (16)

1. Inman WHW, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. Br Med J 1970;2:203-9.
2. Gerstman BB, Piper JM, Freiman JP, et al. Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism. Int J Epidemiol 1975;102:197-208.
3. Vessey MP. Epidemiologic studies of oral contraceptives. Int J Fertil 1989;34(suppl):64-70.
4. Newton JR, d'Arcangues C, Hall PE. A review of "once a month" combined injectable contraceptives. Obstet Gynecol 1994;14:S1-S34.
5. Düsterberg B, Beier S, Schneider WHF, Spona J. Pharmacological features of gestodene in laboratory animals and man. In: Breckwoldt M, Dusterberg B, eds. Gestodene, a new direction in oral contraception. Park Ridge, NJ: Parthenon Publishing Group, 1988:13-29.
6. Spona J, Feichtinger W, Kindermann C, Wünsch C, Brill K. Inhibition of ovulation by an oral contraceptive containing 100 μg levonorgestrel in combination with 20 μg ethinyl estradiol. Contraception 1996;54:299-304.
7. Sartoretto JN, Onega JC. Clinical evaluation of a low dose oestrogen/progestogen combination (100 μg of d-norgestrel and 20 μg of ethinylestradiol). Rev Bras Clin Therap 1974;3:399-404.
8. Vessey MP. Efficacy of different contraceptive methods. Lancet 1982;i:841-2.
9. Speroff L, De Cherney A. Evaluation of a new generation of oral contraceptives. Obstet Gynecol 1993;81:1034-1047.
10. Corson SL. Efficacy and safety of a monophasic and a triphasic oral contraceptive containing norgestimate. Am J Obstet Gynecol 1994;170:1556-61.
11. Endrikat J, Jaques MA, Mayerhofer M, Pelissier C, Müller U, Dústerberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 μg ethinyl estradiol/75 μg gestodene and 20 μg ethinyl estradiol/150 μg desogestrel with respect to efficacy, cycle control and tolerance. Contraception 1995;52:229-35.
12. Akerlund M, Rode A, Westergaard J. Comparative profiles of reliability, cycle control and side effects of two oral contraceptive formulations containing 150 μg desogestrel and either 30 μg or 20 μg ethinyl oestradiol. Br J Obstet Gynaecol 1993;100:832-8.
13. Rosenberg MJ, Long SC. Oral contraceptives and cycle control: a critical review of the literature. Adv Contraception 1992;8:35-45.
14. Düsterberg B, Ellman H, Müller U, Rowe E, Mühe B. A three-year clinical investigation into efficacy, cycle control and tolerability of a new low-dose monophasic oral contraceptive containing gestodene. Gynecol Endocrinol 1996;10:33-9.
15. Kirkman RJE, Pedersen JH, Fioretti P, Roberts HE. Clinical comparison of two low-dose oral contraceptives, Minulet® and Mercilon®, in women over 30 years of age. Contraception 1994;49:33-46.
16. Archer DF, Maheux R, DelConte A, O'Brien FB. A new low-dose monophasic combination oral contraceptive (Alesse®) with levonorgestrel 100 μg and ethinyl estradiol 20 μg. Contraception 1997;55:139-44.